Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis

Company Overview

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.39 to $0.44
• 50-Day Range: $0.40 to $0.81
• 52-Week Range: $0.35 to $4.90
• Volume: 211,194 shs
• Average Volume: 882,678 shs
• Market Capitalization: $11.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Calidi Biotherapeutics Stock Analysis - MarketRank™

Calidi Biotherapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 684th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Calidi Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Calidi Biotherapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($4.48) to ($0.88) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CLDI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Calidi Biotherapeutics does not currently pay a dividend.

Dividend Growth

Calidi Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CLDI.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Calidi Biotherapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

Search Interest

Only 1 people have searched for CLDI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.28% of the stock of Calidi Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.53% of the stock of Calidi Biotherapeutics is held by institutions.

CLDI Stock Analysis - Frequently Asked Questions

How have CLDI shares performed this year?

Calidi Biotherapeutics' stock was trading at $1.15 at the start of the year. Since then, CLDI shares have decreased by 64.3% and is now trading at $0.4104.
View the best growth stocks for 2025 here.

How were Calidi Biotherapeutics' earnings last quarter?

Calidi Biotherapeutics, Inc. (NYSE:CLDI) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.20.

When did Calidi Biotherapeutics' stock split?

Shares of Calidi Biotherapeutics reverse split on the morning of Monday, July 15th 2024. The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Calidi Biotherapeutics' major shareholders?

Top institutional shareholders of Calidi Biotherapeutics include Armistice Capital LLC (11.67%), Belpointe Asset Management LLC (0.88%) and Drive Wealth Management LLC (0.19%).
View institutional ownership trends.

How do I buy shares of Calidi Biotherapeutics?

Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Calidi Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Calidi Biotherapeutics investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Carlyle Secured Lending (CGBD), Devon Energy (DVN) and Hercules Capital (HTGC).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 5/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CLDI
• Previous Symbol: NYSE:CLDI
• CIK: 1855485
• Web: calidibio.com
• Phone: 858-794-9600
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +2,336.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,220,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -344.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $50,000.00
• Price / Sales: 233.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.32) per share
• Price / Book: -0.18

Miscellaneous

• Outstanding Shares: 28,468,000
• Free Float: 20,039,000
• Market Cap: $11.68 million
• Optionable: N/A
• Beta: 1.21